Teriflunomide
It is the main active metabolite of leflunomide. It inhibits the synthesis of pyrimidine and has immunomodulatory, anti-inflammatory and immunosuppressive properties. Indicated in the treatment of multiple sclerosis. Oral administration once a day
Since the last update we have not found published data on its excretion in breastmilk.
Its high binding to plasma proteins makes its transfer to milk in significant concentrations unlikely.
Its slow elimination (half-life of 18-19 days) and its potentially serious side effects means it is recommended that, until there is more published information about this drug in relation to breastfeeding, safer alternatives are used (Alroughani 2016, Almas 2016, Cree 2013), especially during the neonatal period and in case of prematurity.
See below the information of this related product:
- Leflunomide (Very High Risk)
Alternatives
- Glatiramer Acetate (Low Risk probable)
- Interferon Beta-1a (Very Low Risk)
- Methylprednisolone (Very Low Risk)
- Interferon Beta-1b (Very Low Risk)
- Immune-Globulin Human Normal (Very Low Risk)
Very Low Risk
Compatible. Not risky for breastfeeding or infant.
Low Risk
Moderately safe. Mild risk possible. Follow up recommended. Read the Comment.
High Risk
Poorly safe. Evaluate carefully. Use a safer alternative. Read the Comment.
Very High Risk
Not recommended. Cessation of breastfeeding or alternative.
Writings
- Τεριφλουνομίδη (Greek)
- تيريفلونوميد (Arabic)
- Терифлуномид (Cyrillic)
- 特立氟胺 (Chinese)
- C12 H9 F3 N2 O2 (Molecular formula)
- (Z)-2-Cyano-α′α′α-trifluoro-3-hydroxy-p-crotonotoluidide (Chemical name)
- L04AA31 (ATC Code/s)
Drug trade names
References
- Almas S, Vance J, Baker T, Hale T. Management of Multiple Sclerosis in the Breastfeeding Mother. Mult Scler Int. 2016Abstract Full text (link to original source) Full text (in our servers)
- Alroughani R, Altintas A, Al Jumah M, Sahraian M, Alsharoqi I, AlTahan A, Daif A, Dahdaleh M, Deleu D, Fernandez O, Grigoriadis N, Inshasi J, Karabudak R, Taha K, Totolyan N, Yamout BI, Zakaria M, Bohlega S. Pregnancy and the Use of Disease-Modifying Therapies in Patients with Multiple Sclerosis: Benefits versus Risks. Mult Scler Int. 2016Abstract Full text (link to original source) Full text (in our servers)
- Cree BA. Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis. Mult Scler. 2013Abstract Full text (link to original source) Full text (in our servers)